Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised VEF AB (publ) in connection with the listing of the company’s ordinary shares on Nasdaq Stockholm’s Main Market
Mandate

Vinge has advised VEF AB (publ) in connection with the listing of the company’s ordinary shares on Nasdaq Stockholm’s Main Market

June 03, 2022 Capital Markets and Public M&A Corporate Tax

Vinge has advised VEF AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s Main Market. The prospectus was published on 30 May 2022 and the trading on Nasdaq Stockholm commenced on 1 June 2022.

VEF is an investment company that invests in growth stage private fintech companies. VEF focuses on scale emerging markets and invests across all areas of financial services inclusive of payments, credit, mobile money and wealth advisors.

Vinge’s team has primarily consisted of Jesper Schönbeck, Joel Wahlberg, Emma Brolund, Anna Svensson and Johannes Akyol (Capital Markets and Public M&A) and Victor Ericsson and Emelie Svanberg (Corporate Tax).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025